Bronchitis Treatment Market
Bronchitis Treatment Market (Type - Chronic Bronchitis, Acute Bronchitis; Drug Class - Antibiotics, Anti-inflammatory Drugs, Bronchodilator, Mucolytics; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
Press Release :
Bronchitis Treatment Market: Contours of Evolution
Companies investing in bronchitis treatment market are interested in studying the etiology of bronchitis. Key viruses are Influenza type A and B, while key bacterial agents are Streptococcus, Mycoplasma pneumonia, and Staphylococcus. There are several risk factors when population has high disposition to develop chronic bronchitis, particularly in regions where they are exposed to high environmental pollutants. The prevalence of bronchitis is high the general population. In chronic obstructive pulmonary disease (COPD) patients, the prevalence estimates can be as high as 54%. The high burden has been highlighted as a key driver for the evolution of the bronchitis treatment market.
Other key risk factors comprise tobacco smoking, increasing age, socioeconomic status, and occupational exposure. Both pharmacological and non-pharmacological interventions have gathered considerable attention among players in the bronchitis treatment market.
Key types comprise anti-inflammatory drugs, bronchodilators, and mucolytics.
A growing number of epidemiological studies has helped shed light on pharmacological interventions, spurring research on the above segments. The growing morbidity and mortality of acute and chronic bronchitis—the two types--is a key factor driving the bronchitis market.
The bronchitis market stood at US$ 3,432.62 million in 2017 and is projected to rise at CAGR of 3.6% from 2018 to 2026.
The report segments the bronchitis treatment market on the basis of region, type, drug class, and distribution channel.
Chronic bronchitis Segment Vie for Attention Among Researchers and Drug Makers
Among the two types, chronic bronchitis holds the leading share of the global market throughout the forecast period. The rise in the opportunities in this segment is the high morbidity and mortality rate. However, rate of developments in prognosis still seems tepid. Coordinated efforts made by all healthcare teams to improve the outcomes of pharmacological treatment for chronic is a key trend driving prospects in the bronchitis treatment market. Further, clinicians recommend making changes in lifestyle in reducing the morbidity of chronic bronchitis.
On the other hand, acute bronchitis is also garnering attention among drug makers and medical device manufacturers. The segment is expected to keep contributing significant revenues in coming years. In developed countries, given the high incidence, an array of studies have been done to understand the risk factors. These studies shed light on expected avenues in the bronchitis treatment market.
Growing Number of Clinical Trials Help Develop Novel Products
Over the years, nonpharmacological interventions have risen in popularity. The various drugs classes are antibiotics, bronchodilators, mucolytics, and, anti-inflammatory drugs. Of these, bronchodilators have been frequently recommended for the treatment of symptomatic COPD.
Advent of novel LAMA/LABA fixed dose combination inhalers has helped in preventing the exacerbations in COPD patients. Thus, long-acting bronchodilators have attracted research targeted toward improving the mechanism. Growing number of clinical trials has helped develop long-acting bronchodilators. The findings of these studies have paved way to guidelines for reducing COPD exacerbations, thus unlocking new prospects for players in the bronchitis treatment market. Introduction of new drug regimens in COPD treatment options has expanded the horizon for stakeholders in the market. This has also led to the approval of novel LAMA/LABA fixed combinations, opening new doors to opportunities for market players.
Research in Bronchitis Therapeutics Makes North America Key Market
The key regional markets analysed in the study comprise North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Of these, North America and Europe accounted for the major share of the global bronchitis treatment market in 2017. These regional markets have been fuelled by incessant research in bronchitis therapeutics to reduce the morbidity of the disease.
On the other hand, Asia Pacific is expected to be expand at remarkably high CAGR during 2018 – 2026. Several economies are witnessing marked progress in healthcare infrastructures to meet the demand for rising various patient populations. In particular, a robust impetus to the growth of the Asia Pacific bronchitis market comes from growing demand from elderly populations. In the cohort, smoking has been a key risk factor, in the light of other respiratory problems they may be facing. Further, the regional market has seen new avenues for growth due to extensive research and development done to reduce the morbidity of chronic bronchitis due to pollutants. High presence of pollutants in numerous developing economies in Asia has bolstered these research.
Growing Awareness of COPD and High Morbidity of Bronchitis Fuels Asia Pacific Market
Growing awareness of COPD in general population in developing economies is also a favorable trend in the expansion of potential opportunities in the bronchitis treatment market. On the other hand, there has been widespread efforts by governments in several of these nations to make public aware of the risk factors associated with cigarette smoking. Pharmaceutical companies have in recent years have come out with new non-pharmacological interventions, and the electronic media has been promoting the effectiveness of such treatments.
Asia Pacific is thus has large latent opportunities for developers of bronchodilators. The regional market is expected to clock CAGR of 4.0% from 2018 to 2026.
Companies extensively profiled in the report on the bronchitis treatment market are Boehringer Ingelheim International GmbH., Sanofi Aventis, Melinta Therapeutics, Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Novartis AG, and AstraZeneca.
Global Bronchitis Treatment market: Overview
This report analyzes the current and future scenario of the global bronchitis treatment market. Rise in geriatric population, high incidence of bronchitis, and increase in cigarette smoking patient pool are major drivers of the global market.
The global bronchitis treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to segments based on type, drug class, distribution channel, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global bronchitis treatment market.
Global Bronchitis Treatment Market: Key Segments
The global bronchitis treatment market has been segmented based on type, drug class, distribution channel, and region. Furthermore, in terms of type, the market has been divided into chronic bronchitis and acute bronchitis. The chronic bronchitis segment is likely to account for a leading share of the global market during the forecast period owing to high morbidity and mortality rate. Based on drug class, the bronchitis treatment market has been classified into antibiotics, anti-inflammatory drugs, bronchodilators, and mucolytics. In terms of distribution channel, the market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment held a significant share of the market in 2017 due to a rise in the sale of over-the-counter bronchitis therapeutics. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.
Global Bronchitis Treatment Market: Regional Outlook
In terms of region, the global bronchitis treatment market has been segmented into five major regions and key countries/sub-regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and countries/sub-regions have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.
Companies Mentioned in Report
The report also profiles major players in the global bronchitis treatment market based on various attributes such as company overview, financial overview, type portfolio, business strategies, and recent developments. Key players in the global bronchitis treatment market are AstraZeneca, Novartis AG, GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd., Melinta Therapeutics, Sanofi Aventis, and Boehringer Ingelheim International GmbH.
The global bronchitis treatment market has been segmented as given below: